New Stock News | Zai Jiang Pharmaceutical (688266.SH) has once again submitted an application to the Hong Kong Stock Exchange, with four listed drugs including Zepsin.

According to the Hong Kong Stock Exchange's disclosure on August 12, Suzhou Zelgen Biopharmaceutical Co., Ltd. (referred to as: Zelgen Pharmaceuticals (688266.SH)) has submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with CICC acting as the sole sponsor. The company had previously filed its application to the Hong Kong Stock Exchange on December 19, 2025.